Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene

International Journal of Cancer

Volumn 98, Issue 3, 2002, Pages 398-408

  Johns, Terrance G ^a,e   Stockert, Elisabeth ^a   Ritter, Gerd ^a   Jungbluth, Achim A ^a   Su Huang, H J ^b   Cavenee, Webster K ^b   Smyth, Fiona E ^a   Hall, Cathrine M ^a   Watson, Nadine ^c   Nice, Edouard C ^a   Gullick, William J ^d   Old, Lloyd J ^a   Burgess, Antony W ^a   Scott, Andrew M ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF KENT   (United Kingdom)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

Antibody therapy; Epidermal growth factor receptor; Gene amplification; Tumor targeting; Tumor xenografts

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR DE2 7; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; BREAST; CELL SURFACE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM TUMOR; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC IDENTIFICATION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LUNG; LYSOSOME; PRIORITY JOURNAL; PROSTATE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR GENE; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON; PRECIPITIN TESTS; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0037139359     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10189     Document Type: Article

References (42)

1. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII
2. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
3. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
4. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas
5. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- or C-terminal tails
6. Structural alterations of the epidermal growth factor receptor gene in human gliomas
7. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors
8. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors
9. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas
10. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
11. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene
12. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
13. The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target
14. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma
15. Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor
16. Specific targeting of a mutant, activated EGF receptor found in glioblastoma using a monoclonal antibody
17. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
18. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
19. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
20. Long term culture of normal and neoplastic human glia
21. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
22. Stoichiometry, kinetic and binding analysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor
23. Determination of the immuno-reactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
24. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
25. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate
26. Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice
27. Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors
28. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF
29. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
30. Tumor antigens
31. Novel anti-cancer agents in development: Exciting prospects and new challenges
32. Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer
33. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
34. Glycosylation-induced conformational modification positively regulates receptor-receptor association: A study with an aberrant epidermal growth factor receptor (EGFRvIII/DEGFR) expressed in cancer cells
35. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate
36. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine - Cellobiose radio iodination method enhances cellular retention and uptake in tumor xenografts
37. Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores
38. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: Comparison with its murine parent
39. Regulated migration of epidermal growth factor receptor from caveolae
40. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR
41. Monoclonal antibody drug conjugates in the treatment of cancer
42. A new era for radiolabeled antibodies in cancer?